Article Document Academic Article Information Content Entity Journal Article Continuant Continuant Entity Entity Generically Dependent Continuant 2025-06-24T12:39:25 RDF description of � - http://repository.healthpartners.com/individual/document-rn47321 <p>In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged � 6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged � 18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged � 6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses � 2 months after the last recommended COVID-19 vaccine.<p> Hospitalization 18 years with immunocompromising conditions - VISION Network, September 2023-February 2024 public MMWR: Morbidity and Mortality Weekly Report 2025-05-14T21:46:32.386-05:00 24093 document-rn47321 41746 Influenza 73 COVID-19 Vaccines Coronavirus Infections Interim effectiveness of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated hospitalization among adults aged 12 COVID-19 10.15585/mmwr.mm7312a5 Vaccination � Prevention Influenza Vaccines